| __timestamp | Blueprint Medicines Corporation | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 305409000 |
| Thursday, January 1, 2015 | 14456000 | 377080000 |
| Friday, January 1, 2016 | 19218000 | 432829000 |
| Sunday, January 1, 2017 | 27986000 | 496079000 |
| Monday, January 1, 2018 | 47928000 | 557616000 |
| Tuesday, January 1, 2019 | 96388000 | 658498000 |
| Wednesday, January 1, 2020 | 157743000 | 770456000 |
| Friday, January 1, 2021 | 195293000 | 840100000 |
| Saturday, January 1, 2022 | 237374000 | 944700000 |
| Sunday, January 1, 2023 | 295141000 | 1136600000 |
| Monday, January 1, 2024 | 359272000 | 1464300000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Vertex Pharmaceuticals Incorporated and Blueprint Medicines Corporation have demonstrated contrasting strategies in this area. From 2014 to 2023, Vertex Pharmaceuticals saw a steady increase in SG&A expenses, peaking at approximately $1.14 billion in 2023, reflecting a growth of nearly 272% from 2014. In contrast, Blueprint Medicines, while also experiencing an increase, managed a more modest rise of around 3,640% over the same period, reaching $295 million in 2023. This stark difference highlights Vertex's aggressive expansion and investment in administrative capabilities, while Blueprint's leaner approach suggests a focus on strategic cost management. As these companies continue to evolve, their SG&A strategies will remain pivotal in shaping their financial health and competitive edge.
Selling, General, and Administrative Costs: Merck & Co., Inc. vs Blueprint Medicines Corporation
Amgen Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs TG Therapeutics, Inc. Trends and Insights
Vertex Pharmaceuticals Incorporated or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and Galapagos NV
United Therapeutics Corporation or Blueprint Medicines Corporation: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Opthea Limited
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Iovance Biotherapeutics, Inc.
Blueprint Medicines Corporation or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Viridian Therapeutics, Inc.